SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yi-Hsin Weng, Chu-Yu Chen, Kun-Jun Lin, Ying-Ling Chen, Tu-Hsueh Yeh, Ing-Tsung Hsiao, Ing-Jou Chen, Chin-Song Lu, Hung-Li Wang, (R1441C) LRRK2 induces the degeneration of SN dopaminergic neurons and alters the expression of genes regulating neuronal survival in a transgenic mouse model, Experimental Neurology, 2016, 275, 104

    CrossRef

  2. 2
    Sara Bandrés-Ciga, Niccolò Emmanuele Mencacci, Raquel Durán, Francisco Javier Barrero, Francisco Escamilla-Sevilla, Sarah Morgan, Jason Hehir, Francisco Vives, John Hardy, Alan M. Pittman, Analysis of the genetic variability in Parkinson's disease from Southern Spain, Neurobiology of Aging, 2016, 37, 210.e1

    CrossRef

  3. 3
    Letizia Polito, Antonio Greco, Davide Seripa, Genetic Profile, Environmental Exposure, and Their Interaction in Parkinson’s Disease, Parkinson's Disease, 2016, 2016, 1

    CrossRef

  4. 4
    Avner Thaler, Rick C. Helmich, Ayelet Or-Borichev, Bart F.L. Nuenen, Irit Shapira-Lichter, Tanya Gurevich, Avi Orr-Urtreger, Karen Marder, Susan Bressman, Bastiaan R. Bloem, Nir Giladi, Talma Hendler, Anat Mirelman, Intact working memory in non-manifesting LRRK2 carriers – an fMRI study, European Journal of Neuroscience, 2016, 43, 1
  5. 5
    Alastair J. Noyce, Mike A. Nalls, Mendelian Randomization — the Key to Understanding Aspects of Parkinson's Disease Causation?, Movement Disorders, 2016, 31, 1
  6. 6
    Marialuisa Quadri, Xu Yang, Giovanni Cossu, Simone Olgiati, Valeria M. Saddi, Guido J. Breedveld, Limei Ouyang, Jingchu Hu, Na Xu, Josja Graafland, Valeria Ricchi, Daniela Murgia, Leonor Correia Guedes, Claudio Mariani, Maria J. Marti, Patrizia Tarantino, Rosanna Asselta, Francesc Valldeoriola, Monica Gagliardi, Gianni Pezzoli, Mario Ezquerra, Aldo Quattrone, Joaquim Ferreira, Grazia Annesi, Stefano Goldwurm, Eduardo Tolosa, Ben A. Oostra, Maurizio Melis, Jun Wang, Vincenzo Bonifati, An exome study of Parkinson’s disease in Sardinia, a Mediterranean genetic isolate, neurogenetics, 2015, 16, 1, 55

    CrossRef

  7. 7
    Rebecca A. Frake, Thomas Ricketts, Fiona M. Menzies, David C. Rubinsztein, Autophagy and neurodegeneration, Journal of Clinical Investigation, 2015, 125, 1, 65

    CrossRef

  8. 8
    Katie Hall, Sujeong Yang, Olga Sauchanka, Maria Grazia Spillantini, Oleg Anichtchik, Behavioural deficits in transgenic mice expressing human truncated (1–120 amino acid) alpha-synuclein, Experimental Neurology, 2015, 264, 8

    CrossRef

  9. 9
    Amos D. Korczyn, Sharon Hassin-Baer, Can the disease course in Parkinson’s disease be slowed?, BMC Medicine, 2015, 13, 1

    CrossRef

  10. 10
    Rebecca Wallings, Claudia Manzoni, Rina Bandopadhyay, Cellular processes associated with LRRK2 function and dysfunction, FEBS Journal, 2015, 282, 15
  11. 11
    Jan O. Aasly, Oddbjørn Sæther, Krisztina K. Johansen, Tone F. Bathen, Guro F. Giskeødegård, Linda R. White, Changes to Intermediary Metabolites in Sporadic andLRRK2Parkinson’s Disease Demonstrated by Proton Magnetic Resonance Spectroscopy, Parkinson's Disease, 2015, 2015, 1

    CrossRef

  12. 12
    Manabu Funayama, Nobutaka Hattori, CHCHD2 and Parkinson's disease—Authors' reply, The Lancet Neurology, 2015, 14, 7, 682

    CrossRef

  13. 13
    Manabu Funayama, Kenji Ohe, Taku Amo, Norihiko Furuya, Junji Yamaguchi, Shinji Saiki, Yuanzhe Li, Kotaro Ogaki, Maya Ando, Hiroyo Yoshino, Hiroyuki Tomiyama, Kenya Nishioka, Kazuko Hasegawa, Hidemoto Saiki, Wataru Satake, Kaoru Mogushi, Ryogen Sasaki, Yasumasa Kokubo, Shigeki Kuzuhara, Tatsushi Toda, Yoshikuni Mizuno, Yasuo Uchiyama, Kinji Ohno, Nobutaka Hattori, CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study, The Lancet Neurology, 2015, 14, 3, 274

    CrossRef

  14. 14
    Ryan J.H. West, Christopher J.H. Elliott, Alex R. Wade, Classification of Parkinson’s Disease Genotypes in Drosophila Using Spatiotemporal Profiling of Vision, Scientific Reports, 2015, 5, 16933

    CrossRef

  15. 15
    Zeynep S. Agim, Jason R. Cannon, Dietary Factors in the Etiology of Parkinson’s Disease, BioMed Research International, 2015, 2015, 1

    CrossRef

  16. 16
    E. Dragicevic, J. Schiemann, B. Liss, Dopamine midbrain neurons in health and Parkinson’s disease: Emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels, Neuroscience, 2015, 284, 798

    CrossRef

  17. 17
    Pauli Ylikotila, Timo Tiirikka, Jukka S. Moilanen, Helena Kääriäinen, Reijo Marttila, Kari Majamaa, Epidemiology of early-onset Parkinson's disease in Finland, Parkinsonism & Related Disorders, 2015, 21, 8, 938

    CrossRef

  18. 18
    Fathima Shaffra Refai, Shin Hui Ng, Eng-King Tan, EvaluatingLRRK2Genetic Variants with Unclear Pathogenicity, BioMed Research International, 2015, 2015, 1

    CrossRef

  19. 19
    W. M. Johnson, C. Yao, S. L. Siedlak, W. Wang, X. Zhu, G. A. Caldwell, A. L. Wilson-Delfosse, J. J. Mieyal, S. G. Chen, Glutaredoxin deficiency exacerbates neurodegeneration in C. elegans models of Parkinson's disease, Human Molecular Genetics, 2015, 24, 5, 1322

    CrossRef

  20. 20
    Fabrizio Stocchi, Laura Vacca, Fabiana G Radicati, How to optimize the treatment of early stage Parkinson’s disease, Translational Neurodegeneration, 2015, 4, 1, 4

    CrossRef

  21. 21
    Jon Infante, Carlos Prieto, María Sierra, Pascual Sánchez-Juan, Isabel González-Aramburu, Coro Sánchez-Quintana, José Berciano, Onofre Combarros, Jesús Sainz, Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls, Neurobiology of Aging, 2015, 36, 2, 1105

    CrossRef

  22. 22
    André V. Carreiro, Alexandre Mendonça, Mamede de Carvalho, Sara C. Madeira, Integrative biomarker discovery in neurodegenerative diseases, Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2015, 7, 6
  23. 23
    Dafina Angelova, David Brown, Iron, Aging, and Neurodegeneration, Metals, 2015, 5, 4, 2070

    CrossRef

  24. 24
    Ziv Gan-Or, Claire S. Leblond, Victoria Mallett, Avi Orr-Urtreger, Patrick A. Dion, Guy A. Rouleau, LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis, Parkinsonism & Related Disorders, 2015, 21, 7, 778

    CrossRef

  25. 25
    J William Langston, Birgitt Schüle, Linda Rees, R Jeremy Nichols, Carrolee Barlow, Multisystem Lewy body disease and the other parkinsonian disorders, Nature Genetics, 2015, 47, 12, 1378

    CrossRef

  26. 26
    Haley L. Yarosh, Shashwath A. Meda, Harriet de Wit, Amy B. Hart, Godfrey D. Pearlson, Multivariate analysis of subjective responses to d-amphetamine in healthy volunteers finds novel genetic pathway associations, Psychopharmacology, 2015, 232, 15, 2781

    CrossRef

  27. 27
    Mahdi Ghani, Anthony E. Lang, Lorne Zinman, Benedetta Nacmias, Sandro Sorbi, Valentina Bessi, Andrea Tedde, Maria Carmela Tartaglia, Ezequiel I. Surace, Christine Sato, Danielle Moreno, Zhengrui Xi, Rachel Hung, Mike A. Nalls, Andrew Singleton, Peter St George-Hyslop, Ekaterina Rogaeva, Mutation analysis of patients with neurodegenerative disorders using NeuroX array, Neurobiology of Aging, 2015, 36, 1, 545.e9

    CrossRef

  28. 28
    Jie Zhang, Hongmei Dai, Yuanying Deng, Jing Tian, Chen Zhang, Zhiping Hu, Guoying Bing, Lingling Zhao, Neonatal chlorpyrifos exposure induces loss of dopaminergic neurons in young adult rats, Toxicology, 2015, 336, 17

    CrossRef

  29. 29
    Dorit Trudler, Yuval Nash, Dan Frenkel, New insights on Parkinson’s disease genes: the link between mitochondria impairment and neuroinflammation, Journal of Neural Transmission, 2015, 122, 10, 1409

    CrossRef

  30. 30
    Masaki Takahashi, Mari Suzuki, Masashi Fukuoka, Nobuhiro Fujikake, Shoko Watanabe, Miho Murata, Keiji Wada, Yoshitaka Nagai, Hirohiko Hohjoh, Normalization of Overexpressed α-Synuclein Causing Parkinson’s Disease By a Moderate Gene Silencing With RNA Interference, Molecular Therapy—Nucleic Acids, 2015, 4, 5, e241

    CrossRef

  31. 31
    Lorraine V Kalia, Anthony E Lang, Parkinson's disease, The Lancet, 2015, 386, 9996, 896

    CrossRef

  32. 32
    Maria Eugenia Herva, Maria Grazia Spillantini, Parkinson's disease as a member of Prion-like disorders, Virus Research, 2015, 207, 38

    CrossRef

  33. 33
    Mateusz Kurzawski, Monika Białecka, Marek Droździk, Pharmacogenetic considerations in the treatment of Parkinson's disease, Neurodegenerative Disease Management, 2015, 5, 1, 27

    CrossRef

  34. 34
    Agne Kazlauskaite, Miratul M. K. Muqit, PINK1 and Parkin – mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease, FEBS Journal, 2015, 282, 2
  35. 35
    C Gouarné, J Tracz, M Giraudon Paoli, V Deluca, M Seimandi, G Tardif, M Xilouri, L Stefanis, T Bordet, R M Pruss, Protective role of olesoxime against wild-type α-synuclein-induced toxicity in human neuronally differentiated SHSY-5Y cells, British Journal of Pharmacology, 2015, 172, 1
  36. 36
    Martina Zizkova, Rita Sucha, Jirina Tyleckova, Karla Jarkovska, Katerina Mairychova, Eva Kotrcova, Martin Marsala, Suresh Jivan Gadher, Hana Kovarova, Proteome-wide analysis of neural stem cell differentiation to facilitate transition to cell replacement therapies, Expert Review of Proteomics, 2015, 12, 1, 83

    CrossRef

  37. 37
    Ze-Gang Ma, Feng He, Jian Xu, Quantitative assessment of the association between GAK rs1564282 C/T polymorphism and the risk of Parkinson’s disease, Journal of Clinical Neuroscience, 2015, 22, 7, 1077

    CrossRef

  38. 38
    Davide Chiasserini, Silvia Paciotti, Paolo Eusebi, Emanuele Persichetti, Anna Tasegian, Marzena Kurzawa-Akanbi, Patrick F Chinnery, Christopher M Morris, Paolo Calabresi, Lucilla Parnetti, Tommaso Beccari, Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies, Molecular Neurodegeneration, 2015, 10, 1

    CrossRef

  39. 39
    Pradeep K. Kurup, Jian Xu, Rita Alexandra Videira, Chimezie Ononenyi, Graça Baltazar, Paul J. Lombroso, Angus C. Nairn, STEP61is a substrate of the E3 ligase parkin and is upregulated in Parkinson’s disease, Proceedings of the National Academy of Sciences, 2015, 112, 4, 1202

    CrossRef

  40. 40
    Connie Marras, Subtypes of Parkinsonʼs disease, Current Opinion in Neurology, 2015, 28, 4, 382

    CrossRef

  41. 41
    Danielle D. Feng, Waijiao Cai, Xiqun Chen, The associations between Parkinson’s disease and cancer: the plot thickens, Translational Neurodegeneration, 2015, 4, 1

    CrossRef

  42. 42
    Lucas Nürnberger, Christine Klein, Simon Baudrexel, Julia Roggendorf, Marcel Hildner, Shu Chen, Jun-Suk Kang, Rüdiger Hilker, Johann Hagenah, Ultrasound-based motion analysis demonstrates bilateral arm hypokinesia during gait in heterozygous PINK1 mutation carriers, Movement Disorders, 2015, 30, 3
  43. 43
    Lars Tönges, Éva M. Szegö, Patrizia Hause, Kim-Ann Saal, Lars Tatenhorst, Jan Christoph Koch, Zara d`Hedouville, Vivian Dambeck, Sebastian Kügler, Christoph P. Dohm, Mathias Bähr, Paul Lingor, Alpha-synuclein mutations impair axonal regeneration in models of Parkinson's disease, Frontiers in Aging Neuroscience, 2014, 6,

    CrossRef

  44. 44
    Min Kyung Chu, Won Chan Kim, Jung Mi Choi, Jeong-Hoon Hong, Suk Yun Kang, Hyeo-Il Ma, Yun Joong Kim, Analysis of Dosage Mutation inPARK2among Korean Patients with Early-Onset or Familial Parkinson's Disease, Journal of Clinical Neurology, 2014, 10, 3, 244

    CrossRef

  45. 45
    Eleanna Kara, Georgia Xiromerisiou, Cleanthe Spanaki, Maria Bozi, Georgios Koutsis, Marios Panas, Efthimios Dardiotis, Styliani Ralli, Jose Bras, Christopher Letson, Connor Edsall, Hannah Pliner, Sampath Arepalli, Kallirhoe Kalinderi, Liana Fidani, Sevasti Bostantjopoulou, Margaux F. Keller, Nicholas W. Wood, John Hardy, Henry Houlden, Leonidas Stefanis, Andreas Plaitakis, Dena Hernandez, Georgios M. Hadjigeorgiou, Mike A. Nalls, Andrew B. Singleton, Assessment of Parkinson's disease risk loci in Greece, Neurobiology of Aging, 2014, 35, 2, 442.e9

    CrossRef

  46. 46
    Monika Białecka, Mateusz Kurzawski, Anna Roszmann, Piotr Robowski, Emilia J. Sitek, Krystyna Honczarenko, Monika Mak, Monika Deptuła-Jarosz, Monika Gołąb-Janowska, Marek Droździk, Jarosław Sławek, BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease, Neuroscience Letters, 2014, 561, 86

    CrossRef

  47. 47
    Marina Picillo, Angelo Ranieri, Giuseppe Orefice, Vincenzo Bonifati, Paolo Barone, Clinical progression of SYNJ1-related early onset atypical parkinsonism: 3-year follow up of the original Italian family, Journal of Neurology, 2014, 261, 4, 823

    CrossRef

  48. 48
    David Burn, Daniel Weintraub, Bernard Ravina, Irene Litvan, Cognition in movement disorders: Where can we hope to be in ten years?, Movement Disorders, 2014, 29, 5
  49. 49
    Sergio Montes, Susana Rivera-Mancia, Araceli Diaz-Ruiz, Luis Tristan-Lopez, Camilo Rios, Copper and Copper Proteins in Parkinson’s Disease, Oxidative Medicine and Cellular Longevity, 2014, 2014, 1

    CrossRef

  50. 50
    Alex R Wade, Christopher JH Elliott, Could the detection of visual disturbances associated with Parkinson’s disease genes in flies lead to new treatments for the disease?, Neurodegenerative Disease Management, 2014, 4, 4, 291

    CrossRef

  51. 51
    Jan O. Aasly, Krisztina K. Johansen, Gunnar Brønstad, Bjørg J. Warø, Nour K. Majbour, Shiji Varghese, Fatimah Alzahmi, Katerina E. Paleologou, Dena A. M. Amer, Abdulmonem Al-Hayani, Omar M. A. El-Agnaf, Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers, Frontiers in Aging Neuroscience, 2014, 6,

    CrossRef

  52. 52
    S. Little, P. Brown, Focusing Brain Therapeutic Interventions in Space and Time for Parkinson’s Disease, Current Biology, 2014, 24, 18, R898

    CrossRef

  53. 53
    Hao Deng, Lamei Yuan, Genetic variants and animal models in SNCA and Parkinson disease, Ageing Research Reviews, 2014, 15, 161

    CrossRef

  54. 54
    Vincenzo Bonifati, Genetics of Parkinson's disease – state of the art, 2013, Parkinsonism & Related Disorders, 2014, 20, S23

    CrossRef

  55. 55
    Iakov N. Rudenko, Mark R. Cookson, Heterogeneity of Leucine-Rich Repeat Kinase 2 Mutations: Genetics, Mechanisms and Therapeutic Implications, Neurotherapeutics, 2014, 11, 4, 738

    CrossRef

  56. 56
    Ramin Ansari, Ali Mahta, Eric Mallack, Jin Jun Luo, Hyperhomocysteinemia and Neurologic Disorders: a Review, Journal of Clinical Neurology, 2014, 10, 4, 281

    CrossRef

  57. 57
    Renée Vancraenenbroeck, Joren De Raeymaecker, Evy Lobbestael, Fangye Gao, Marc De Maeyer, Arnout Voet, Veerle Baekelandt, Jean-Marc Taymans, In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2, Frontiers in Molecular Neuroscience, 2014, 7,

    CrossRef

  58. 58
    Eugénie Mutez, Aurore Nkiliza, Karim Belarbi, Amélie de Broucker, Christel Vanbesien-Mailliot, Séverine Bleuse, Aurélie Duflot, Thomas Comptdaer, Pierre Semaille, Renaud Blervaque, David Hot, Frederic Leprêtre, Martin Figeac, Alain Destée, Marie-Christine Chartier-Harlin, Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson's disease, Neurobiology of Disease, 2014, 63, 165

    CrossRef

  59. 59
    Loukia Parisiadou, Jia Yu, Carmelo Sgobio, Chengsong Xie, Guoxiang Liu, Lixin Sun, Xing-Long Gu, Xian Lin, Nicole A Crowley, David M Lovinger, Huaibin Cai, LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity, Nature Neuroscience, 2014, 17, 3, 367

    CrossRef

  60. 60
    Lars Brichta, Paul Greengard, Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update, Frontiers in Neuroanatomy, 2014, 8,

    CrossRef

  61. 61
    Hongyan Li, Aishanjiang Yusufujiang, Shaliya Naser, Yi Zhu, Mayinur Maimaiti, Xiaoyan He, Juan Bu, Xuegang Meng, Mingyuan Wang, Jiang Li, Baiting Dina, Lijuan Yang, Zuhere Nayi, Hui Dang, Chengfeng Wang, Dilimulati Amiti, Asiya Aji, Nazuke Yusufu, Yan Jiao, Fengmei Duan, Mutation analysis of PARK2 in a Uyghur family with early-onset Parkinson's disease in Xinjiang, China, Journal of the Neurological Sciences, 2014, 342, 1-2, 21

    CrossRef

  62. 62
    Yuequn Li, Yonghua Li, Shuchao Pang, Wenhui Huang, Aimei Zhang, Robert G. Hawley, Bo Yan, Novel and functional ABCB1 gene variant in sporadic Parkinson’s disease, Neuroscience Letters, 2014, 566, 61

    CrossRef

  63. 63
    P. Gómez-Suaga, E. Fdez, B. Fernández, M. Martínez-Salvador, M. Blanca Ramírez, J. Madero-Pérez, P. Rivero-Ríos, J.M. Fuentes, S. Hilfiker, Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease, Neuropharmacology, 2014, 85, 45

    CrossRef

  64. 64
    Hannah M. Kersten, Richard H. Roxburgh, Helen V. Danesh-Meyer, Ophthalmic manifestations of inherited neurodegenerative disorders, Nature Reviews Neurology, 2014, 10, 6, 349

    CrossRef

  65. 65
    Artur F Schumacher-Schuh, Carlos RM Rieder, Mara H Hutz, Parkinson's disease pharmacogenomics: new findings and perspectives, Pharmacogenomics, 2014, 15, 9, 1253

    CrossRef

  66. 66
    Wang Yunfu, Liu Guangjian, Zhong Ping, Sun Yanpeng, Fang Xiaoxia, Hu Wei, Yuan Jiang, Hu Jingquan, Wang Songlin, Zhang Hongyan, Liu Yong, Chen Shi, PINK1 and Its Familial Parkinson's Disease-Associated Mutation Regulate Brain Vascular Endothelial Inflammation, Journal of Molecular Neuroscience, 2014, 53, 1, 109

    CrossRef

  67. 67
    Beth-Anne Sieber, Story Landis, Walter Koroshetz, Randall Bateman, Andrew Siderowf, Wendy R. Galpern, John Dunlop, Steven Finkbeiner, Margaret Sutherland, Hao Wang, Virginia M.-Y. Lee, Harry T. Orr, Katrina Gwinn, Kip Ludwig, Anna Taylor, Christine Torborg, Thomas J. Montine, Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson'sDisease 2014 conference, Annals of Neurology, 2014, 76, 4
  68. 68
    K. D. Dijk, M. Bidinosti, A. Weiss, P. Raijmakers, H. W. Berendse, W. D. J. Berg, Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity, European Journal of Neurology, 2014, 21, 3
  69. 69
    Jose A. Santiago, Judith A. Potashkin, System-based approaches to decode the molecular links in Parkinson's disease and diabetes, Neurobiology of Disease, 2014, 72, 84

    CrossRef

  70. 70
    Caroline M. Tanner, Samuel M. Goldman, G. Webster Ross, Stephen J. Grate, The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk, Alzheimer's & Dementia, 2014, 10, 3, S213

    CrossRef

  71. 71
    Jose A Obeso, Maria C Rodriguez-Oroz, Maria Stamelou, Kailash P Bhatia, David J Burn, The expanding universe of disorders of the basal ganglia, The Lancet, 2014, 384, 9942, 523

    CrossRef

  72. 72
    Glenda M. Halliday, James B. Leverenz, Jay S. Schneider, Charles H. Adler, The neurobiological basis of cognitive impairment in Parkinson's disease, Movement Disorders, 2014, 29, 5
  73. 73
    Emiko Miura, Takafumi Hasegawa, Masatoshi Konno, Mari Suzuki, Naoto Sugeno, Nobuhiro Fujikake, Sven Geisler, Mitsuaki Tabuchi, Ryuji Oshima, Akio Kikuchi, Toru Baba, Keiji Wada, Yoshitaka Nagai, Atsushi Takeda, Masashi Aoki, VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease, Neurobiology of Disease, 2014, 71, 1

    CrossRef

  74. 74
    E. Arenas, Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine for Parkinson's disease, Journal of Molecular Cell Biology, 2014, 6, 1, 42

    CrossRef

  75. 75
    Meera Saxena, Animal Models for Huntington's and Parkinson's Diseases, Materials and Methods, 2013, 3,

    CrossRef

  76. 76
    Lei Zhang, Marialuisa Quadri, Leonor Correia Guedes, Miguel Coelho, Anabela Valadas, Tiago Mestre, Patrícia Pita Lobo, Mário Miguel Rosa, Erik Simons, Ben A. Oostra, Joaquim J. Ferreira, Vincenzo Bonifati, Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: Identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants, Parkinsonism & Related Disorders, 2013, 19, 10, 897

    CrossRef

  77. 77
    Marialuisa Quadri, Mingyan Fang, Marina Picillo, Simone Olgiati, Guido J. Breedveld, Josja Graafland, Bin Wu, Fengping Xu, Roberto Erro, Marianna Amboni, Sabina Pappatà, Mario Quarantelli, Grazia Annesi, Aldo Quattrone, Hsin F. Chien, Egberto R. Barbosa, Ben A. Oostra, Paolo Barone, Jun Wang, Vincenzo Bonifati, Mutation in the SYNJ1 Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism, Human Mutation, 2013, 34, 9
  78. 78
    Paul M. A. Antony, Nico J. Diederich, Rejko Krüger, Rudi Balling, The hallmarks of Parkinson's disease, FEBS Journal, 2013, 280, 23
  79. 79
    C. Warren Olanow, Jose A. Obeso, Fabrizio Stocchi, The Vatican Meeting on Neuroprotection for Parkinson's Disease, Movement Disorders, 2013, 28, 1
  80. 80
    Md Shahaduzzaman, Sandra Acosta, Paula C. Bickford, Cesar V. Borlongan, α-Synuclein is a pathological link and therapeutic target for Parkinson’s disease and traumatic brain injury, Medical Hypotheses, 2013, 81, 4, 675

    CrossRef

  81. 81
    Karin Tuschl, Philippa B. Mills, Peter T. Clayton, Metal Related Neurodegenerative Disease, 2013,

    CrossRef